ABSTRACT
The transmission networks of SARS-CoV-2 in sub-Saharan Africa remain poorly understood. We analyzed 684 genomes from samples collected across six counties in coastal Kenya during the first two waves (March 2020 -February 2021). Up to 32 Pango lineages were detected in the local sample with six accounting for 88.0% of the sequenced infections: B.1 (60.4%), B.1.1 (8.9%), B.1.549 (7.9%), B.1.530 (6.4%), N.8 (4.4%) and A (3.1%). In a contemporaneous global sample, 571 lineages were identified, 247 for Africa and 88 for East Africa. We detected 262 location transition events comprising: 64 viral imports into Coastal Kenya; 26 viral exports from coastal Kenya; and 172 inter-county import/export events. Most international viral imports (61%) and exports (88%) occurred through Mombasa, a key coastal touristic and commercial center; and many occurred prior to June 2020, when stringent local COVID-19 restriction measures were enforced. After this period, local transmission dominated, and distinct local phylogenies were seen. Our analysis supports moving control strategies from a focus on international travel to local transmission.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
This work was supported by the National Institute for Health Research (NIHR) (project references 17/63/82 (PI Prof. James Nokes) and 16/136/33 (PI Prof. Mark Wooolhouse) using UK aid from the UK Government to support global health research, The UK Foreign, Commonwealth and Development Office and Wellcome Trust (grant# 220985). The views expressed in this publication are those of the author (s) and not necessarily those of NIHR, the Department of Health and Social Care, Foreign Commonwealth and Development Office, Wellcome Trust or the UK government. Some members of COVID-19 Testing Team at KWTRP were supported by funding received by Dr Marta Maia (BOHEMIA study funded UNITAID), Dr Francis Ndungu (Senior Fellowship and Research and Innovation Action (RIA) grants from EDCTP) and Prof. Anthony Scott (PCIVS grant from GAVI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Samples analysed here were collected under the Ministry of Health (MoH) protocols as part of the national response to the COVID-19 pandemic. The whole genome sequencing study protocol was reviewed and approved by the Scientific and Ethics Review Committee (SERU), Kenya Medical Research Institute (KEMRI), Nairobi, Kenya (SERU #4035). Individual patient consent was not required by the committee for the use of these samples for genomic surveillance to inform public health response.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Coastal Kenya genomes have been deposited to both GISAID (Accession numbers: EPI_ISL_1039223-29; EPI_ISL1440075-109, IPI_ISL_457845-931; EPI_ISL_568695-872; EPI_ISL806548-717; EPI_ISL_855494-548; EPI_ISL_968807-9245).
